Egle Therapeutics: EGL-003 Phase 1 shows clean safety, Treg lift
Egle Therapeutics has reported positive Phase 1 single ascending dose data for EGL-003, its Treg-selective interleukin-2 agonist, showing a favourable early safety profile and pronounced, selective expansion of regulatory T cells across all four dose levels tested in healthy volunteers. The data were presented on 30 September at the 35th EADV Congress in Vienna.
The study enrolled 24 healthy volunteers receiving a single subcutaneous dose at 0.5, 1.5, 2.5 or 5 µg/kg. No serious adverse events were reported at any dose. Injection-site reactions were mild and self-limited, and flu-like symptoms were confined to the two highest cohorts, with one moderate case of headache at 2.5 µg/kg. All other adverse events were Grade 1.
Pharmacodynamic findings
On the pharmacodynamic side, EGL-003 produced 8- to 21-fold increases in activated Treg populations across the dose range, sustained for up to 28 days, without corresponding expansion of conventional CD4, CD8 or NK cell populations. Upregulation of suppressive-function markers including FoxP3, CTLA-4, ICOS and HLA-DR was dose-dependent and consistent. Plasma IL-10, an anti-inflammatory cytokine regarded as an indicator of regulatory immune activity, rose in parallel with Treg expansion.
A particularly notable finding relates to skin trafficking. Egle observed expansion of cutaneous lymphocyte antigen-positive Tregs followed by a subsequent decline in circulating levels of that population, a kinetic pattern the company interprets as consistent with migration from the bloodstream into skin tissue. CLA-negative Tregs, by contrast, remained elevated in circulation. Egle acknowledges that disease-modification and maintenance-dosing hypotheses based on these findings require further clinical validation.
Chief Medical Officer Kenji Hashimoto said the "depth and durability of Treg expansion," combined with functional and phenotypic markers of activity, gave the team confidence in the mechanism as it moves into the next study stage.
MAD study and competitive context
Egle plans to begin a multiple ascending dose proof-of-concept study in moderate-to-severe atopic dermatitis in Q4 2026. The double-blind, placebo-controlled, randomised trial will enrol approximately 50 to 100 adults at a starting dose of 1.5 µg/kg every four weeks, with cohorts escalating to 5 µg/kg on four- or two-week schedules. The primary endpoint is safety; secondary endpoints include the Eczema Area and Severity Index and validated Investigator Global Assessment. Preliminary efficacy data are targeted for Q2 2027, with a full assessment expected in Q4 2027.
The atopic dermatitis market is intensely competitive. Dupilumab, the IL-4/IL-13 receptor antagonist from Sanofi and Regeneron, has become a blockbuster standard of care, while lebrikizumab and tralokinumab offer further IL-13-targeted options. JAK inhibitors including upadacitinib and abrocitinib add a small-molecule layer. Egle's upstream Treg-rebalancing approach is mechanistically distinct from all of these, aiming to restore immune homeostasis rather than block individual cytokine pathways. A handful of other groups, including some academic spinouts, are also exploring IL-2 pathway modulation in autoimmunity, making the MAD efficacy readout in 2027 a watched data point across the sector.
Chief Executive John Celebi framed the opportunity around the roughly 21.2 million addressable moderate-to-severe patients in the US and EU, noting that many fail to achieve durable control on existing therapies. The MAD study will be the first test of whether EGL-003's selective Treg biology translates to clinical benefit in patients rather than healthy volunteers.